Subtopic Deep Dive
Acute Myeloid Leukemia Classification
Research Guide
What is Acute Myeloid Leukemia Classification?
Acute Myeloid Leukemia Classification standardizes AML subtyping using morphological, genetic, immunophenotypic, and clinical criteria from FAB, WHO, and ELN systems to guide risk-adapted therapies.
WHO classifications evolved from 2008 (Vardiman et al., 2009, 4374 citations) to 2016 revisions (Arber et al., 2016, 9991 citations), incorporating genomic biomarkers. FAB criteria originated in 1985 (Bennett et al., 1985, 2944 citations) with subtypes like AML-M0 (Bennett et al., 1991, 666 citations). ELN integrates MRD for prognosis (Heuser et al., 2021, 651 citations). Over 30,000 citations across key papers.
Why It Matters
Precise AML classification enables risk-stratified treatments, improving survival in high-risk subtypes via targeted therapies. Arber et al. (2016) updated WHO criteria to include biomarkers like NPM1 and FLT3 mutations, guiding venetoclax-based regimens. Heuser et al. (2021) standardized MRD assessment, predicting relapse and informing transplant decisions. NCCN guidelines (O’Donnell et al., 2017, 650 citations) apply classifications to frontline therapy selection.
Key Research Challenges
Genomic Heterogeneity Integration
AML exhibits complex mutations requiring multi-omics integration beyond morphology. Arber et al. (2016) highlight challenges in defining recurrent genetic abnormalities. Standardization across labs remains inconsistent (Heuser et al., 2021).
MRD Detection Sensitivity
MRD assays vary in sensitivity for flow cytometry vs. PCR methods. Heuser et al. (2021) note ELN consensus gaps in low-burden disease detection. Prognostic thresholds need refinement for therapy adaptation.
Risk Score Refinement
Prognostic systems like IPSS-R (Greenberg et al., 2012, 3050 citations) struggle with AML-MDS overlap. Dynamic scoring incorporating MRD lags behind static models. Inter-study variability complicates meta-analyses.
Essential Papers
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian et al. · 2016 · Blood · 10.0K citations
Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identi...
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman, Jüergen Thiele, Daniel A. Arber et al. · 2009 · Blood · 4.4K citations
Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the...
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg, Heinz Tuechler, Julie Schanz et al. · 2012 · Blood · 3.0K citations
Abstract The International Prognostic Scoring Sytem (IPSS) is an important standard for ssessing prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS). To refine the IP...
Proposed Revised Criteria for the Classification of Acute Myeloid Leukemia
John M. Bennett, DANIEL CATOVSKY, MARIE T. DANIEL et al. · 1985 · Annals of Internal Medicine · 2.9K citations
Position Papers1 October 1985Proposed Revised Criteria for the Classification of Acute Myeloid LeukemiaA Report of the French-American-British Cooperative GroupJOHN M. BENNETT, M.D., DANIEL CATOVSK...
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Rory M. Shallis, Rong Wang, Amy J. Davidoff et al. · 2019 · Blood Reviews · 879 citations
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith, Kari Bohlke, Gary H. Lyman et al. · 2015 · Journal of Clinical Oncology · 876 citations
Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical Oncology convened ...
Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO)
John M. Bennett, Daniel Catovsky, M‐T. Daniel et al. · 1991 · British Journal of Haematology · 666 citations
Summary. We describe a form of acute myeloid leukaemia (AML), designated AML‐MO, with minimal myeloid differentiation, not included previously in the FAB classification. AML‐MO cannot be diagnosed ...
Reading Guide
Foundational Papers
Start with Bennett et al. (1985, 2944 citations) for FAB origins, then Vardiman et al. (2009, 4374 citations) for WHO baseline, and Bennett et al. (1991) for AML-M0 addition to grasp morphological evolution.
Recent Advances
Study Arber et al. (2016, 9991 citations) for genomic WHO update and Heuser et al. (2021, 651 citations) for MRD consensus to understand current standards.
Core Methods
Core techniques: morphology (FAB), cytogenetics/immunophenotyping (WHO), flow/PCR MRD (ELN), prognostic scoring (IPSS-R).
How PapersFlow Helps You Research Acute Myeloid Leukemia Classification
Discover & Search
Research Agent uses citationGraph on Arber et al. (2016) to map WHO evolution from Vardiman et al. (2009), then findSimilarPapers for ELN MRD papers like Heuser et al. (2021). exaSearch queries 'AML WHO 2022 updates' to uncover post-2016 guidelines beyond provided lists. searchPapers with 'measurable residual disease AML ELN' retrieves 651-citation Heuser paper clusters.
Analyze & Verify
Analysis Agent applies readPaperContent to extract MRD thresholds from Heuser et al. (2021), then verifyResponse with CoVe against Arber et al. (2016) for classification consistency. runPythonAnalysis processes citation counts via pandas for impact ranking; GRADE grading scores WHO evidence as high due to consensus methodology.
Synthesize & Write
Synthesis Agent detects gaps in MRD integration between WHO (Arber et al., 2016) and ELN (Heuser et al., 2021), flagging contradictions in risk groups. Writing Agent uses latexEditText for classification tables, latexSyncCitations to link Bennett et al. (1985), and latexCompile for review-ready manuscript; exportMermaid diagrams FAB-to-WHO evolution.
Use Cases
"Run survival analysis on IPSS-R scores from Greenberg 2012 AML cohort data."
Research Agent → searchPapers 'IPSS-R AML' → Analysis Agent → readPaperContent (Greenberg et al., 2012) → runPythonAnalysis (pandas Kaplan-Meier plot, NumPy hazard ratios) → matplotlib survival curve output.
"Generate LaTeX table comparing FAB vs WHO AML subtypes with citations."
Synthesis Agent → gap detection (FAB Bennett 1985 vs WHO Arber 2016) → Writing Agent → latexEditText (subtype matrix) → latexSyncCitations (Vardiman 2009, Bennett 1985) → latexCompile → PDF table export.
"Find GitHub repos implementing ELN MRD flow cytometry pipelines."
Research Agent → searchPapers 'ELN MRD AML flow cytometry code' → paperExtractUrls (Heuser 2021 supplements) → paperFindGithubRepo → githubRepoInspect → verified analysis scripts for MRD quantification.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers 'AML classification WHO ELN' → citationGraph (Arber 2016 hub) → DeepScan 7-steps analyzes 50+ papers with GRADE scoring → structured report on subtype outcomes. Theorizer generates hypotheses on MRD-WHO integration: readPaperContent (Heuser 2021 + Arber 2016) → contradiction flagging → theory on unified scoring. DeepScan verifies NCCN guideline adherence (O’Donnell 2017) via CoVe chain.
Frequently Asked Questions
What defines Acute Myeloid Leukemia Classification?
AML classification uses FAB (Bennett et al., 1985), WHO (Arber et al., 2016), and ELN criteria integrating morphology, genetics, immunophenotype, and MRD for risk subtyping.
What are core classification methods?
FAB subtypes blasts morphologically (M0-M7; Bennett et al., 1985; 1991). WHO adds genetics like t(8;21) (Arber et al., 2016). ELN incorporates MRD by flow/PCR (Heuser et al., 2021).
What are key papers?
Arber et al. (2016, 9991 citations) updated WHO; Vardiman et al. (2009, 4374 citations) prior revision; Bennett et al. (1985, 2944 citations) FAB origin; Heuser et al. (2021, 651 citations) MRD.
What open problems exist?
Challenges include MRD assay standardization (Heuser et al., 2021), genomic complexity integration (Arber et al., 2016), and dynamic risk models beyond IPSS-R (Greenberg et al., 2012).
Research Hematological disorders and diagnostics with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Acute Myeloid Leukemia Classification with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers